The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Incyte Corp (NASDAQ: INCY) closed at $86.28 in the last session, down -0.48% from day before closing price of $86.7. In other words, the price has decreased by -$0.48 from its previous closing price. On the day, 1.79 million shares were traded. INCY stock price reached its highest trading level at $88.6624 during the session, while it also had its lowest trading level at $86.17.
Ratios:
We take a closer look at INCY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.59. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 2.85. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On August 01, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $90.
Stifel Upgraded its Hold to Buy on June 16, 2025, while the target price for the stock was maintained at $107.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 02 ’25 when SHEILA DENTON bought 599 shares for $87.65 per share.
BARRY FLANNELLY bought 17,447 shares of INCY for $1,487,531 on Sep 18 ’25. On Sep 16 ’25, another insider, Denton Sheila A., who serves as the EVP & General Counsel of the company, sold 278 shares for $83.15 each. As a result, the insider received 23,116 and left with 33,200 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 16848424960 and an Enterprise Value of 14469095424. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.61, and their Forward P/E ratio for the next fiscal year is 12.24. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.20. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.67 while its Price-to-Book (P/B) ratio in mrq is 4.02. Its current Enterprise Value per Revenue stands at 3.156 whereas that against EBITDA is 13.638.
Stock Price History:
The Beta on a monthly basis for INCY is 0.73, which has changed by 0.27841163 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, INCY has reached a high of $87.99, while it has fallen to a 52-week low of $53.56. The 50-Day Moving Average of the stock is 4.39%, while the 200-Day Moving Average is calculated to be 21.77%.
Shares Statistics:
According to the various share statistics, INCY traded on average about 1.74M shares per day over the past 3-months and 1894820 shares per day over the past 10 days. A total of 194.12M shares are outstanding, with a floating share count of 192.93M. Insiders hold about 1.20% of the company’s shares, while institutions hold 102.25% stake in the company. Shares short for INCY as of 1757894400 were 8697013 with a Short Ratio of 5.01, compared to 1755216000 on 9603401. Therefore, it implies a Short% of Shares Outstanding of 8697013 and a Short% of Float of 6.29.
Earnings Estimates
. The current market rating for Incyte Corp (INCY) reflects the collective analysis of 15.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $1.75, with high estimates of $2.02 and low estimates of $1.46.
Analysts are recommending an EPS of between $6.52 and $4.84 for the fiscal current year, implying an average EPS of $6.02. EPS for the following year is $7.17, with 20.0 analysts recommending between $9.22 and $3.42.
Revenue Estimates
According to 18 analysts,. The current quarter’s revenue is expected to be $1.26B. It ranges from a high estimate of $1.31B to a low estimate of $1.21B. As of. The current estimate, Incyte Corp’s year-ago sales were $1.14BFor the next quarter, 18 analysts are estimating revenue of $1.32B. There is a high estimate of $1.41B for the next quarter, whereas the lowest estimate is $1.27B.
A total of 20 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $4.94B, while the lowest revenue estimate was $4.77B, resulting in an average revenue estimate of $4.85B. In the same quarter a year ago, actual revenue was $4.24BBased on 20 analysts’ estimates, the company’s revenue will be $5.34B in the next fiscal year. The high estimate is $5.71B and the low estimate is $4.87B.
